EBITDA at other companies
Other financials
Where this comes from
Calculated from Nurix Therapeutics, Inc.’s reported figures.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s EBITDA?
- Nurix Therapeutics, Inc. (NRIX) reported EBITDA of -$90.3M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s EBITDA changed year-over-year?
- Nurix Therapeutics, Inc.'s EBITDA decreased by 49.2% year-over-year, from -$60.51M to -$90.3M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s EBITDA has grown at a 24.5% compound annual growth rate (CAGR), from -$115.19M to -$276.93M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.